SCHEMBL4676901

SCHEMBL4676901

Cc1ccc(Cc2csc(C(=O)C=C(O)C(=O)O)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 4/20 0.36
CACNA1G O43497 1/20 0.36
CACNA1H O95180 1/20 0.36
CACNA1I Q9P0X4 1/20 0.36
SRD5A2 P31213 1/20 0.35
LTA4H P09960 1/20 0.35
AOC3 Q16853 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
NPC1 O15118 3/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
CTBP2 P56545 1/20 0.33
PTGER1 P34995 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676899 1.00 RAB9A (0.39) RAB9AKDM4EGAAALDH1A1CACNA1G
SCHEMBL4675737 0.88 PTGER1 (0.41) RAB9AKDM4EALDH1A1NPC1SMN1; SMN2
SCHEMBL4675741 0.88 PTGER1 (0.41) RAB9AKDM4EALDH1A1NPC1SMN1; SMN2
SCHEMBL4676333 0.88 KMT2A (0.43) ALDH1A1CACNA1GCACNA1HCACNA1IAOC3
SCHEMBL4676339 0.88 KMT2A (0.43) ALDH1A1CACNA1GCACNA1HCACNA1IAOC3
SCHEMBL4671473 0.87 LMNA (0.42) RAB9AKDM4EGAAALDH1A1CACNA1G
SCHEMBL4671477 0.87 LMNA (0.42) RAB9AKDM4EGAAALDH1A1CACNA1G
SCHEMBL4672538 0.87 HDAC1 (0.37) KDM4EALDH1A1CACNA1GCACNA1HCACNA1I
SCHEMBL4672541 0.87 HDAC1 (0.37) KDM4EALDH1A1CACNA1GCACNA1HCACNA1I
SCHEMBL4672839 0.86 ALDH1A1 (0.45) RAB9AKDM4EGAAALDH1A1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 RAB9A 2021/4885KDM4E 947/4885GAA 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.